These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 23924054

  • 1. Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.
    Pineo CB, Hitzeroth II, Rybicki EP.
    Plant Biotechnol J; 2013 Oct; 11(8):964-75. PubMed ID: 23924054
    [Abstract] [Full Text] [Related]

  • 2. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M, Fochesato M, Miseur A, Mertens E, Dendouga N, Brendle S, Balogh KK, Christensen ND, Giannini SL.
    J Virol; 2016 Jul 15; 90(14):6314-25. PubMed ID: 27147749
    [Abstract] [Full Text] [Related]

  • 3. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine.
    Hassan SW, Waheed MT, Müller M, Clarke JL, Shinwari ZK, Lössl AG.
    Hum Vaccin Immunother; 2014 Jul 15; 10(10):2975-82. PubMed ID: 25483463
    [Abstract] [Full Text] [Related]

  • 4. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B, Schellenbacher C, Shafti-Keramat S, Jindra C, Christensen N, Kirnbauer R.
    PLoS One; 2017 Jul 15; 12(1):e0169533. PubMed ID: 28056100
    [Abstract] [Full Text] [Related]

  • 5. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S, Spagnoli G, Bulli L, Balz K, Yang F, Odenwald C, Seitz H, Mariz FC, Bolchi A, Ottonello S, Müller M.
    J Virol; 2018 Feb 15; 92(4):. PubMed ID: 29212932
    [Abstract] [Full Text] [Related]

  • 6. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C, Roden RBS, Kirnbauer R.
    Virus Res; 2017 Mar 02; 231():166-175. PubMed ID: 27889616
    [Abstract] [Full Text] [Related]

  • 7. Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.
    Diamos AG, Larios D, Brown L, Kilbourne J, Kim HS, Saxena D, Palmer KE, Mason HS.
    Vaccine; 2019 Jan 03; 37(1):137-144. PubMed ID: 30459071
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine.
    Namvar A, Bolhassani A, Javadi G, Noormohammadi Z.
    Sci Rep; 2019 Oct 23; 9(1):15225. PubMed ID: 31645650
    [Abstract] [Full Text] [Related]

  • 15. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
    Tumban E, Peabody J, Peabody DS, Chackerian B.
    PLoS One; 2011 Oct 23; 6(8):e23310. PubMed ID: 21858066
    [Abstract] [Full Text] [Related]

  • 16. Plastid expression of a double-pentameric vaccine candidate containing human papillomavirus-16 L1 antigen fused with LTB as adjuvant: transplastomic plants show pleiotropic phenotypes.
    Waheed MT, Thönes N, Müller M, Hassan SW, Gottschamel J, Lössl E, Kaul HP, Lössl AG.
    Plant Biotechnol J; 2011 Aug 23; 9(6):651-60. PubMed ID: 21447051
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K, Ishii Y, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    Virology; 2007 Feb 20; 358(2):266-72. PubMed ID: 17010405
    [Abstract] [Full Text] [Related]

  • 19. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
    Kondo K, Ochi H, Matsumoto T, Yoshikawa H, Kanda T.
    J Med Virol; 2008 May 20; 80(5):841-6. PubMed ID: 18360909
    [Abstract] [Full Text] [Related]

  • 20. A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11.
    Slupetzky K, Gambhira R, Culp TD, Shafti-Keramat S, Schellenbacher C, Christensen ND, Roden RB, Kirnbauer R.
    Vaccine; 2007 Mar 01; 25(11):2001-10. PubMed ID: 17239496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.